Forest Labs Q1 Profit Tops Views

Pharmaceutical company Forest Laboratories reported Tuesday a profit in for the first quarter that more-than-doubled from last year, reflecting revenue growth and lower charges. Both adjusted earnings per share and quarterly revenues topped analysts' expectations.

The New York-based company reported net income of $258.14 million or $0.90 per share for the first quarter, up from $117.48 million or $0.39 per share in the prior-year quarter.

Results for the latest quarter included a charge of $40 million or $0.14 per share for a new product licensing fee. The year-ago results included a charge of $50 million or $0.17 per share for a new product licensing fee, and a charge of $148.4 million or $0.39 per share related to a U.S. Department of Justice settlement.

Excluding items, adjusted earnings for the quarter grew to $1.04 per share from last year's $0.95 last year. On average, 25 analysts polled by Thomson Reuters expected the company to earn $0.97 per share in the quarter. Analysts' estimates typically exclude special items.

Net revenues for the quarter grew to $1.15 billion from $1.07 billion in the same quarter last year, and topped 16 Wall Street analysts' consensus estimate of $1.13 billion.

Net sales improved 8.2% to $1.10 billion from last year, and contract revenue edged up to $40.64 million from $39.80 a year ago, while interest income was $5.58 million, down from $7.01 million last year.

Product-wise, sales of Lexapro, for the initial and maintenance treatment of major depressive disorder, grew 3.2% to $585.7 million from last year. Sales of Namenda, for the treatment of moderate and severe Alzheimer's disease, grew 3.9% to $319.9 million, and sales of Bystolic, for hypertension, were up 31% to $78 million from a year ago.

The company's newest product Savella, for the management of fibromyalgia, recorded sales of $25.8 million, 25.6% higher than last year.

 

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.